ClinicalTrials.gg
Active, not recruitingNCT06445985Updated Jan 30, 2025

Hydrotherapy in Duchenne Muscular Dystrophy (DMD)

An interventional study of Hydrotherapy in Duchenne Muscular Dystrophy, sponsored by Lancashire Teaching Hospitals NHS Foundation Trust. Active, not recruiting at 1 site in United Kingdom. Open to male participants aged 6 Years to 25 Years. Per ClinicalTrials.gov, last updated 2025-01-30.

Sponsored by Lancashire Teaching Hospitals NHS Foundation Trust · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as active, not recruiting.
  • Registered 1 year 3 months after the study started (first participant enrolled Nov 2022, registered Feb 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Non-randomized
Ages
6 Years to 25 Years
Sex
Male
01

Study summary

The goal of this clinical trial aims to establish if there are meaningful benefits to providing a hydrotherapy service for young people with Duchenne muscular dystrophy (DMD). The main aims are to: 1. to allocate a clinical physiotherapist to a project implementing hydrotherapy in young patients with DMD to establish whether there are meaningful benefits to their daily life. 2. to conduct patient and parent interviews to understand the barriers to completing a hydrotherapy intervention and ensure future research addresses meaningful outcomes for those with DMD.

Read the detailed description

The quality of life in young males with Duchenne muscular dystrophy (DMD) is negatively impacted by daily pain, changes in body composition and a lack of support to undertake physical activity. Hydrotherapy represents a potential means of involving boys and adolescents with DMD in activity that could benefit the negative factors influencing their quality of life. There are presently no guidelines or evidence for the benefits of hydrotherapy with the standards of care for young males with DMD.

This trial will provide evidence that will allow care providers to advocate the use of hydrotherapy within the management of DMD, as an inclusive activity, that can be adopted by those with DMD who are either ambulatory, or non-ambulatory. Through 12-weeks of hydrotherapy, the trial will investigate whether there are benefits to physical function, pain and quality of life. These measures represent meaningful outcomes in the progression of DMD, and have direct patient impact for those affected by DMD. On completion of the hydrotherapy, there will be a series of interviews with some of the participants and their parents. The aim of these interviews is to understand participant and parent barriers to hydrotherapy, and uncover whether hydrotherapy improves the lives of the participants beyond simple clinical measures and questionnaires.

The study aims recruit 44 boys and young men with Duchenne muscular dystrophy. Patients will be recruited from NHS neuromuscular services and through families who attend the local hospice.

Following an informed consent process they will enter the first 12 week stage, as a control to observe and measure their habitual physical activity, along with monitoring their diet. They will then enter the intervention stage where they will have a weekly physiotherapy led pool session with a number of physical activities. During the hydrotherapy period, participants will access the hydrotherapy pool once a week for 12 weeks. Sessions are supervised by an experienced physiotherapist, who will guide the exercise for a session lasting 30 to 60 minutes.

The exercises, intensity and specific hydrotherapy plan will be derived from consultation with the participants and their parents. Due to the variance within the presentation of the condition, and the inclusive age range within the study, an externally valid approach to exercise prescription will be utilised. Diet and physical function will be measured during this stage.

There will be a number of assessments to be completed at 3 time points. As much as possible these will be arranged as single visits. The first before the control period, the second after the control period, and the third after the hydrotherapy period. The assessments include a number of physical assessments, including assessments of function and ability, body mass and quality of life. After completion, all participants will be invited to complete a qualitative interview, in particular enquiring about the experience and logistics of hydrotherapy.

02

Conditions studied

  • Duchenne Muscular Dystrophy
03

In context

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 108 are open to participants now.

This study's enrollment of 31 is above the median of 26 across 332 interventional studies indexed under Muscular Dystrophy, Duchenne.

Browse Muscular Dystrophy, Duchenne studies →

Lead sponsor

Lancashire Teaching Hospitals NHS Foundation Trust is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 25 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Established diagnosis of Duchenne Muscular Dystrophy (either by genetics or muscle )
  • Between 6 and 25 years of age
  • On stable dose of or not on steroids

Exclusion criteria

Exclusion Criteria:

  • Younger than 6 years, older than 25 years
  • Recent change in dose, less than 3 months prior
  • Undertaking formal hydrotherapy supervised by physiotherapist on a regular basis (weekly or more frequent)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • No intervention
    Control

    Participants will have a 12 week period where they will continue with their habitual physical activity behaviour. Diet and physical activity will be monitored

  • Active comparator
    Hydrotherapy

    Participants will complete 12-weeks of hydrotherapy, involving up to 60 mins of hydrotherapy once a week. Diet and physical activity will be monitored.

    Other: Hydrotherapy

Interventions

  • OtherHydrotherapy

    Physiotherapy led pool session

06

What researchers measure

Primary outcomes

  1. Body Mass via Bioelectrical impedance (BIA)

    Fat mass, body fat percentage and fat free mass will be measured using BIA (bioelectrical impedance). BIA has been validated in DMD and is accurate enough to measure longitudinal changes in body composition and muscle mass in this population

    Time frame: 24 weeks

  2. Pain Scale

    A pain map assessment of the topographic distribution of daily pain will also be competed, consistent with our previous work in DMD. Scale of 1-10

    Time frame: 24 weeks

  3. PedsQL QoL / DMD QoL - Quality of Life

    PedsQL QoL - Quality of Life for both participants, and the DMD-QoL Proxy for parents - Scale of 0-4

    Time frame: 24 weeks

Secondary outcomes

  1. Upper Limb Strength

    Upper limb strength using grip and pinch measure using digital, handheld dynamometers North-Star

    Time frame: 24 weeks

  2. Range of Motion

    Limited ankle range of motion (ROM) Ankle plantarflexion-dorsiflexion (PF-DF ROM) will be assessed through a goniometer

    Time frame: 24 weeks

  3. Pulmonary function

    Pulmonary function will be assessed using digital spirometry

    Time frame: 24 weeks

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — The results of this study will be used to inform the neuromuscular service in Preston and at other sites in the UK. The results will also be shared more widely by presenting them at regional and or national meetings. The results may be published in a scientific journal and presented at scientific medical conferences and through publications and meetings organised by Duchenne UK.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06445985
Lead sponsor
Lancashire Teaching Hospitals NHS Foundation Trust
Collaborators
Duchenne UK
Responsible party
Sponsor
First posted
Jun 6, 2024
Start date
Nov 2, 2022
Primary completion
Apr 1, 2025 (estimated)
Completion
Dec 12, 2025 (estimated)
Last update
Jan 30, 2025

Study contacts

Christian De Goede
principal investigator · Lancashire Teaching Hospitals NHS Foundation Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion